返回 Agendas
Tuesday Oral Presentations - Professional Poster Session 1B
Session Chair(s)
Julie Ho
Associate Director, Business and Market Development
DIA, United States
New this year! Join us in the Exhibit Hall Poster Area (Hall A Entrance) for a series of 5 minute presentations delivered by this year’s Professional Poster Presenters. View this year’s Professional Poster Program Schedule and Poster Details
The following are scheduled in this session 1B:
- 11:35 - 11:40amT 12 Feasibility of Replacing the Thorough QT (TQT) Study with Intense ECG Data Collection in Early Clinical Studies
- 11:42 - 11:47am T 13 Assessing Bias in Administrative Database Studies of Vaccine Completion Due to Excluding Subjects with Incomplete Follow-up
- 11:49 - 11:54am T14 Design and Development of an eCOA Specific Solution for Capturing Patient Data in Diabetes Clinical Trials
- 11:56 am - 12:01pm T 15 Engage Patients with Innovative Global Digital Patient Platform
- 12:03 - 12:08pm T 19 Drug Lag and Approval Time Metrics - Are They Good Markers to Assess the Global Regulatory Environment?
- 12:10 - 12:15pm T 20 Analyzing Global Recruitment Strategies to Improve Local Trial Enrollment - A Global Investigation Into “What Works Where” for Patient Recruitment and Retention Tools and Techniques
- 12:17 - 12:22pm T 22 Monitoring Interactive Response Technology Vendor Implemented Randomization and Dosing Systems
- 12:24 - 12:29pm T 23 Evolution of a Unique Blend of Business Process and Technology to Enhance Medical Affairs Capabilities
- 12:31 - 12:36pm T 25 A Pitfall in the Clinical Study Enrollment of Postmenopausal Females
- 12:38 - 12:43pm T 27 Lack of Inter-Ethnic Difference in QT-Susceptibility to Moxifloxacin: Two Independent TQT Studies in Caucasian and Asian Populations
- 12:45 - 12:50pm T 28 Implementing Quality Risk Management and Risk-Based Monitoring: Practical Guidelines from Sponsors and Sites
- 12:52 - 12:57pm T 29 Measurement Equivalence of the SF-36v2 on a Handheld Device and Smartphone App
- 12:59 - 1:04pm T 30 How to Maximize Data Quality in Retrospective Chart Review Studies
- 1:06 - 1:11pm T 31 Benefit-Risk Assessments (BRAs) of an Established Products’ Portfolio
- 1:13 - 1:18pm T 33 Results of An Online Survey of Stakeholders Regarding Barriers and Solutions to Clinical Trial Recruitment
- 1:20 - 1:25pm T 34 Process for Ensuring Clinical Trial Product Quality
- 1:27 - 1:32pm T 42 Results Reporting to ClinicalTrials.gov and EudraCT - A Consolidated Approach and First-hand Experiences
注册方法
Registration override should work.